Japanese Dividend Stocks Drawing Income Investors As Bond Yields Stay High

With US 10Y Treasury yields hovering near 20 month highs, the income from government bonds has become far more competitive. That pulls attention away from lower yielding equities and puts a spotlight on Dividend Powerhouses with yields above 5% that aim for stable, well covered and growing payouts. This article walks through 3 stocks from the screener that may appeal if you want income that keeps working for you.

The three Dividend Powerhouses highlighted below are just a starting sample, with the full screen surfacing 458 more companies that feature similarly compelling income stories not covered here. Head straight into the Dividend Powerhouses (3%+ Yield) screener to identify, filter and analyze the ideas that best fit your own income strategy.

Canon (TSE:7751)

Canon is a diversified Japanese equipment company best known to most investors for its printers, cameras and medical imaging systems. The Printing Business Unit provides recurring hardware, supplies and service income that backs its Dividend Powerhouse profile. The stock has a market value of about ¥3.9t, which places it firmly in large cap territory for investors seeking sizeable, established dividend payers.

Canon may interest income focused investors who want more than just a high headline yield. The long running printing and document solutions franchise throws off steady cash flow, recent earnings growth was very strong, and the stock currently trades well below one estimate of fair value. Together these factors support the case for a well covered payout. At the same time, the record of dividend stability is not perfect and the business relies fully on external funding, so payout decisions and future cash generation still deserve careful scrutiny.

Canon’s strong cash generation and valuation gap could be telling a richer story about the durability of its Dividend Powerhouse status. Get the full picture in the DCF valuation analysis for Canon

Tokio Marine Holdings (TSE:8766)

Tokio Marine Holdings is a large Japanese insurer that focuses on non life and life insurance, using recurring underwriting and investment income to support its dividend profile. It generates most of its revenue from overseas insurance at about ¥5,408b, with another ¥3,163b from domestic property and casualty insurance and around ¥445b from domestic life insurance, supported by smaller solution and other businesses of about ¥328b. The stock has a market value of roughly ¥13,959b, putting it firmly in mega cap territory.

Tokio Marine appeals if you want income backed by a long running insurance franchise rather than a one off payout story. The group combines sizeable domestic P&C and life operations with a larger overseas book, which together underpin recurring premiums and investment income that can support a 3%+ dividend yield. Recent buybacks, including about ¥287,399.43 million repurchased under the March 2026 plan, signal a management team actively returning capital to shareholders. At the same time, thinner profit margins, reliance on divesting equity holdings and exposure to areas like North American commercial real estate loans mean the dividend still depends on disciplined execution. The real question is whether that mix of income strength and active capital management offsets these pressure points over the next few years.

Tokio Marine’s mix of recurring premiums and active buybacks hints at a story that many income investors may be underestimating. See how the capital flows, margins and payout risks line up in the analysis report for Tokio Marine Holdings

Daiichi Sankyo Company (TSE:4568)

Daiichi Sankyo is a Japan based pharmaceutical company focused on prescription medicines such as oncology therapies, anticoagulants and cardiovascular and metabolic drugs. Its inclusion in the Dividend Powerhouses theme comes from a portfolio of established, widely marketed drugs like Enhertu, Lixiana/Savaysa and Olmetec based combinations that generate relatively steady cash flow, which can support a well covered dividend even though the company is not dividend first in its priorities. All of its ¥2,223.2b of revenue is reported under a single Pharmaceutical Operation segment, and the stock has a market value of about ¥5,158.1b, putting it firmly in large pharma territory.

Daiichi Sankyo gives you a mix of dependable, cash generating mature drugs and high potential oncology medicines, led by Enhertu and Datroway, that continue to secure new approvals and reimbursement in major markets through 2026. That combination supports a yield above 3% along with scope for potential dividend growth. However, the dividend is not yet well covered by free cash flow, and earnings still depend heavily on a handful of blockbuster products. If expansion in areas such as HER2 positive and HER2 mutant cancers proceeds in line with indications from recent trial results, the income profile may evolve in ways that are not apparent from current coverage metrics alone.

Daiichi Sankyo’s oncology pipeline keeps expanding while cash generation from established drugs still carries the dividend. However, the real story is how future approvals may reshape that balance. See how the income, growth and product risk picture fits together in the analyst forecasts for Daiichi Sankyo Company

Seeking Alternatives Before The Crowd Moves

Fresh income ideas do not stay under the radar for long. As yields shift and momentum builds, others will move first. Scan these curated lists and get in early.

• Spot cash rich companies that aim for resilience before headlines catch up by running the list of solid balance sheet and fundamentals (41 results) and shortlisting stocks that match your risk appetite.
• Seek exposure to artificial intelligence momentum while it still feels early by scanning the 54 AI infrastructure stocks for companies building the picks and shovels of this shift.
• Explore opportunities in precious metals by reviewing the 32 elite gold producer stocks and flagging producers that suit your income and diversification goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com